Second Line Durvalumab plus Tremelimumab
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Second Line Durvalumab plus Tremelimumab

Sponsor: AstraZeneca

Immunotherapy with durvalumab plus tremelimumab or durvalumab alone for patients with previously treated, metastatic urothelial carcinoma of the urinary tract (including the urinary bladder, ureter, urethra and renal pelvis).